Ontak denileukin diftitox: Phase II data; marketed to treat persistent or recurrent CTCL

In a Phase II trial in 25 evaluable patients, 1 patient had a complete response, 4 had partial responses, and 8 had stable disease for an overall response rate of 52% (13/25). Adverse events that occu...